Biodesix (NASDAQ: BDSX) reclassifies Q4 2025 results release as filed
Filing Impact
Filing Sentiment
Form Type
8-K/A
Rhea-AI Filing Summary
Biodesix, Inc. filed an amended current report to change how its recent earnings press release is treated under securities law. The company previously issued a press release with certain preliminary and unaudited financial results for the fourth quarter and year ended December 31, 2025. Through this amendment, Biodesix is recharacterizing that press release, which is attached as Exhibit 99.1, so that it is considered "filed" rather than "furnished" under the Exchange Act. The company states that no other changes have been made beyond this filing status update.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
FAQ
What did Biodesix (BDSX) change in this 8-K/A filing?
Biodesix, Inc. filed an amended current report solely to recharacterize its January 12, 2026 press release with preliminary and unaudited Q4 and full-year 2025 results as filed rather than furnished.
Does this Biodesix 8-K/A include new financial results for 2025?
No new figures are described here. The amendment refers to an existing press release with preliminary and unaudited results for the fourth quarter and year ended December 31, 2025, which is attached as Exhibit 99.1.
Why is the Biodesix Q4 and 2025 results press release now being treated as filed?
The company states that the information in Item 2.02 of this amended report, including Exhibit 99.1, is being filed for purposes of Section 18 of the Exchange Act and may be incorporated by reference into other Biodesix filings.
What exhibit is attached to this Biodesix (BDSX) 8-K/A?
Exhibit 99.1 is the press release issued by Biodesix, Inc. dated January 12, 2026, containing certain preliminary and unaudited financial results. Exhibit 104 is the cover page interactive data file embedded in Inline XBRL.
Were there any other changes made in this Biodesix 8-K amendment?
The company states that this amendment was filed solely to recharacterize the earnings press release as filed rather than furnished and that no other changes have been made.